Cargando…
Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting
Background: Checking Helicobacter pylori susceptibility tests in the clinical setting before first-line treatment is considered difficult. We compared susceptibility-guided therapy (SGT) with empirical therapy (ET) as a first-line treatment containing clarithromycin and investigated the eradication...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924850/ https://www.ncbi.nlm.nih.gov/pubmed/33669969 http://dx.doi.org/10.3390/antibiotics10020214 |
_version_ | 1783659177953984512 |
---|---|
author | Kang, Seokin Kim, Yuri Ahn, Ji Yong Jung, Hwoon-Yong Kim, Nayoung Na, Hee Kyong Lee, Jeong Hoon Jung, Kee Wook Kim, Do Hoon Choi, Kee Don Song, Ho June Lee, Gin Hyug |
author_facet | Kang, Seokin Kim, Yuri Ahn, Ji Yong Jung, Hwoon-Yong Kim, Nayoung Na, Hee Kyong Lee, Jeong Hoon Jung, Kee Wook Kim, Do Hoon Choi, Kee Don Song, Ho June Lee, Gin Hyug |
author_sort | Kang, Seokin |
collection | PubMed |
description | Background: Checking Helicobacter pylori susceptibility tests in the clinical setting before first-line treatment is considered difficult. We compared susceptibility-guided therapy (SGT) with empirical therapy (ET) as a first-line treatment containing clarithromycin and investigated the eradication rate using antimicrobial susceptibility testing (AST). Methods: 257 patients with H. pylori infection, with AST, performed before the eradication of clarithromycin-containing regimens were enrolled and divided into two groups: the SGT and ET groups. Results: Eradication rates in the SGT and ET groups were 85.4% and 58.4% (P < 0.01), respectively. In triple therapy (TT), eradication rates of the SGT and ET groups were 85.1% and 56.6% (P < 0.01), respectively. In sequential therapy (SET), eradication rates of the SGT and ET groups were 86.2% and 65.6% (P = 0.06), respectively. According to AST, TT had an eradication rate of 84.6% with strains susceptible to clarithromycin and amoxicillin and 11.1% with strains resistant to both. SET had an eradication rate of 89.5% with strains susceptible to clarithromycin, amoxicillin, and metronidazole, whereas it was 0% with strains resistant to clarithromycin and metronidazole. Conclusions: SGT as first-line treatment improved eradication rates of TT and SET by 28.5 (P < 0.01) and 20.6 (P = 0.06) percent points, respectively, compared with ET. |
format | Online Article Text |
id | pubmed-7924850 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79248502021-03-03 Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting Kang, Seokin Kim, Yuri Ahn, Ji Yong Jung, Hwoon-Yong Kim, Nayoung Na, Hee Kyong Lee, Jeong Hoon Jung, Kee Wook Kim, Do Hoon Choi, Kee Don Song, Ho June Lee, Gin Hyug Antibiotics (Basel) Article Background: Checking Helicobacter pylori susceptibility tests in the clinical setting before first-line treatment is considered difficult. We compared susceptibility-guided therapy (SGT) with empirical therapy (ET) as a first-line treatment containing clarithromycin and investigated the eradication rate using antimicrobial susceptibility testing (AST). Methods: 257 patients with H. pylori infection, with AST, performed before the eradication of clarithromycin-containing regimens were enrolled and divided into two groups: the SGT and ET groups. Results: Eradication rates in the SGT and ET groups were 85.4% and 58.4% (P < 0.01), respectively. In triple therapy (TT), eradication rates of the SGT and ET groups were 85.1% and 56.6% (P < 0.01), respectively. In sequential therapy (SET), eradication rates of the SGT and ET groups were 86.2% and 65.6% (P = 0.06), respectively. According to AST, TT had an eradication rate of 84.6% with strains susceptible to clarithromycin and amoxicillin and 11.1% with strains resistant to both. SET had an eradication rate of 89.5% with strains susceptible to clarithromycin, amoxicillin, and metronidazole, whereas it was 0% with strains resistant to clarithromycin and metronidazole. Conclusions: SGT as first-line treatment improved eradication rates of TT and SET by 28.5 (P < 0.01) and 20.6 (P = 0.06) percent points, respectively, compared with ET. MDPI 2021-02-21 /pmc/articles/PMC7924850/ /pubmed/33669969 http://dx.doi.org/10.3390/antibiotics10020214 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kang, Seokin Kim, Yuri Ahn, Ji Yong Jung, Hwoon-Yong Kim, Nayoung Na, Hee Kyong Lee, Jeong Hoon Jung, Kee Wook Kim, Do Hoon Choi, Kee Don Song, Ho June Lee, Gin Hyug Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting |
title | Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting |
title_full | Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting |
title_fullStr | Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting |
title_full_unstemmed | Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting |
title_short | Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting |
title_sort | role of antimicrobial susceptibility testing before first-line treatment containing clarithromycin for helicobacter pylori eradication in the clinical setting |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924850/ https://www.ncbi.nlm.nih.gov/pubmed/33669969 http://dx.doi.org/10.3390/antibiotics10020214 |
work_keys_str_mv | AT kangseokin roleofantimicrobialsusceptibilitytestingbeforefirstlinetreatmentcontainingclarithromycinforhelicobacterpylorieradicationintheclinicalsetting AT kimyuri roleofantimicrobialsusceptibilitytestingbeforefirstlinetreatmentcontainingclarithromycinforhelicobacterpylorieradicationintheclinicalsetting AT ahnjiyong roleofantimicrobialsusceptibilitytestingbeforefirstlinetreatmentcontainingclarithromycinforhelicobacterpylorieradicationintheclinicalsetting AT junghwoonyong roleofantimicrobialsusceptibilitytestingbeforefirstlinetreatmentcontainingclarithromycinforhelicobacterpylorieradicationintheclinicalsetting AT kimnayoung roleofantimicrobialsusceptibilitytestingbeforefirstlinetreatmentcontainingclarithromycinforhelicobacterpylorieradicationintheclinicalsetting AT naheekyong roleofantimicrobialsusceptibilitytestingbeforefirstlinetreatmentcontainingclarithromycinforhelicobacterpylorieradicationintheclinicalsetting AT leejeonghoon roleofantimicrobialsusceptibilitytestingbeforefirstlinetreatmentcontainingclarithromycinforhelicobacterpylorieradicationintheclinicalsetting AT jungkeewook roleofantimicrobialsusceptibilitytestingbeforefirstlinetreatmentcontainingclarithromycinforhelicobacterpylorieradicationintheclinicalsetting AT kimdohoon roleofantimicrobialsusceptibilitytestingbeforefirstlinetreatmentcontainingclarithromycinforhelicobacterpylorieradicationintheclinicalsetting AT choikeedon roleofantimicrobialsusceptibilitytestingbeforefirstlinetreatmentcontainingclarithromycinforhelicobacterpylorieradicationintheclinicalsetting AT songhojune roleofantimicrobialsusceptibilitytestingbeforefirstlinetreatmentcontainingclarithromycinforhelicobacterpylorieradicationintheclinicalsetting AT leeginhyug roleofantimicrobialsusceptibilitytestingbeforefirstlinetreatmentcontainingclarithromycinforhelicobacterpylorieradicationintheclinicalsetting |